A latent contingency table approach to dose finding for combinations of two agents

Biometrics

Volumn 65, Issue 3, 2009, Pages 866-875

  Yin, Guosheng ^a   Yuan, Ying ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adaptive design; Bayesian estimation; Combining drugs; Gibbs sampling; Maximum tolerated dose; Phase I trial; Synergy; Toxicity

Indexed keywords

BAYESIAN NETWORKS; MEDICAL APPLICATIONS;

ADAPTIVE DESIGNS; BAYESIAN ESTIMATIONS; COMBINING DRUG; DOSE FINDING; GIBBS SAMPLING; MAXIMUM TOLERATED DOSE; PHASE I; PHASE I TRIAL; SYNERGY; TWO AGENTS;

TOXICITY;

CANCER; DESIGN; PARAMETERIZATION; SYNERGISM;

ARTICLE; BAYES THEOREM; BIVARIATE ANALYSIS; CLINICAL TRIAL; COHORT ANALYSIS; CONTINGENCY TABLE; DOSE CALCULATION; MAXIMUM TOLERATED DOSE; PROBABILITY; SIMULATION; STATISTICAL PARAMETERS; TOXICITY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG THERAPY, COMPUTER-ASSISTED; DRUG TOXICITY; HUMANS; MAXIMUM TOLERATED DOSE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; SAMPLE SIZE;

EID: 70349251729     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/j.1541-0420.2008.01119.x     Document Type: Article

References (27)

1. Abdelbasit, K. M. and Plackett, R. L. (1982). Experimental design for joint action. Biometrics 38, 171 179.
2. Ashford, J. R. (1981). General models for the joint action of mixtures of drugs. Biometrics 37, 457 474.
3. Babb, J., Rogatko, A., and Zacks, S. (1998). Cancer phase I clinical trials: Efficient dose escalation with overdose control. Statistics in Medicine 17, 1103 1120. (Pubitemid 28221028)
4. Chevret, S. (2006). Statistical Methods for Dose-Finding Experiments. Chichester, U.K. : John Wiley and Sons Ltd.
5. Conaway, M. R., Dunbar, S., and Peddada, S. D. (2004). Designs for single- or multiple-agent phase I trials. Biometrics 60, 661 669.
6. Durham, S. D., Flournoy, N., and Rosenberger, W. F. (1997). A random walk rule for phase I clinical trials. Biometrics 53, 745 760.
7. Gasparini, M. and Eisele, J. (2000). A curve-free method for phase I clinical trials. Biometrics 56, 609 615.
8. Gilks, W. R., Best, N. G., and Tan, K. K. C. (1995). Adaptive rejection Metropolis sampling within Gibbs sampling. Applied Statistics 44, 455 472.
9. Goodman, S. N., Zahurak, M. L., and Piantadosi, S. (1995). Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 14, 1149 1161.
10. Haines, L. M., Perevozskaya, I., and Rosenberger, W. F. (2003). Bayesian optimal designs for phase I clinical trials. Biometrics 59, 591 600.
11. Huang, X., Biswas, S., Oki, Y., Issa, J. P., and Berry, D. A. (2007). A parallel phase III clinical trial design for combination therapies. Biometrics 63, 429 436.
12. Kramar, A., Lebecq, A., and Candalh, E. (1999). Continual reassessment methods in phase I trials of the combination of two agents in oncology. Statistics in Medicine 18, 1849 1864.
13. Kuzuya, K., Ishikawa, H., Nakanishi, T., Kikkawa, F., Nawa, A., Fujimura, H., Iwase, A., Arii, Y., Kawai, M., Hattori, S., Sakakibara, K., Sasayama, E., Furuhashi, Y., Suzuki, T., and Mizutani, S. (2001). Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: A phase I modified continual reassessment method study. International Journal of Clinical Oncology 6, 271 278.
14. Leung, D. H.-Y. and Wang, Y.-G. (2002). An extension of the continual reassessment method using decision theory. Statistics in Medicine 21, 51 63.
15. Lokich, J. (2001). Phase I clinical trial of weekly combined topotecan and irinotecan. American Journal Clinical Oncology 24, 336 340.
16. Møller, S. (1995). An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Statistics in Medicine 14, 911 922.
17. Murtaugh, P. A. and Fisher, L. D. (1990). Bivariate binary models of efficacy and toxicity in dose-ranging trials. Communications in Statistics, Part A - Theory and Methods 19, 2003 2020.
18. O'Quigley, J., Pepe, M., and Fisher, L. (1990). Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 46, 33 48.
19. Simon, R. and Korn, E. (1990). Selecting agent combinations based on total equivalent dose (dose intensity). Journal of the National Cancer Institute 82, 1469 1476.
20. Storer, B. E. (1989). Design and analysis of phase I clinical trials. Biometrics 45, 925 937.
21. Stylianou, M. and Flournoy, N. (2002). Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 58, 171 177.
22. Thall, P. F., Millikan, R. E., Müller, P., and Lee, S.-J. (2003). Dose-finding with two agents in phase I oncology trials. Biometrics 59, 487 496.
23. Ting, N. (2006). Dose Finding in Drug Development. New York : Springer.
24. Wang, K. and Ivanova, A. (2005). Two-dimensional dose finding in discrete dose space. Biometrics 61, 217 222.
25. Whitehead, J. and Brunier, H. (1995). Bayesian decision procedures for dose determining experiments. Statistics in Medicine 14, 885 893.
26. Yin, G. and Yuan, Y. (2008). Bayesian dose finding for drug combinations by copula regression. Applied Statistics, tentatively accepted.
27. Yuan, Z., Chappell, R., and Bailey, H. (2007). The continual reassessment method for multiple toxicity grades: A Bayesian quasi-likelihood approach. Biometrics 63, 173 179.